EVECARE

Main information

  • Trade name:
  • EVECARE 30 CAP
  • Pharmaceutical form:
  • CAP
  • Composition:
  • 30
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • EVECARE 30 CAP
    India
  • Language:
  • English

Other information

Status

  • Source:
  • Central Drugs Standard Control Organization
  • Last update:
  • 09-08-2016

17-7-2018

New York-based food processors agree to stop food preparation operations due to food safety violations

New York-based food processors agree to stop food preparation operations due to food safety violations

New York-based food processors agree to stop food preparation operations due to food safety violations

FDA - U.S. Food and Drug Administration

27-6-2018

Regulatory and procedural guideline:  Quality Review of Documents general principles regarding the summary-of-product-characteristics information for a generic / hybrid / biosimilar product

Regulatory and procedural guideline: Quality Review of Documents general principles regarding the summary-of-product-characteristics information for a generic / hybrid / biosimilar product

This document outlines the general principles to follow for the preparation of the summary of product characteristics (SmPC) for a generic, hybrid or biosimilar medicinal product to be authorised via the centralised procedure using a reference medicinal product authorised either at national level or centrally.

Europe - EMA - European Medicines Agency

13-6-2018

Scientific guideline:  Concept paper on preparation of a revised guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, draft: consultation open

Scientific guideline: Concept paper on preparation of a revised guideline on the evaluation of medicinal products indicated for treatment of bacterial infections, draft: consultation open

This concept paper proposes the development of a single guideline on the clinical evaluation of medicinal products indicated for treatment of bacterial infections. The development of this single guideline is intended to merge, revise and add to the guidance that is currently included in two separate documents as follows: guideline on the evaluation of medicinal products indicated for treatment of bacterial infections (CPMP/EWP/558/95 Rev. 2), adopted in 2011 and in force since 2012 and the addendum ...

Europe - EMA - European Medicines Agency

3-5-2018

ARGB is being restructured for publication in July 2018

ARGB is being restructured for publication in July 2018

In preparation for the restructure of the ARGB in July, we have restructured some of the biologicals sections of the TGA website

Therapeutic Goods Administration - Australia